research use only
Cat.No.S4127
| Related Targets | CXCR Hedgehog/Smoothened PKA AChR 5-HT Receptor Histamine Receptor Dopamine Receptor Ras KRas GPR |
|---|---|
| Other Adrenergic Receptor Inhibitors | ICI 118551 Hydrochloride (Zenidolol) L755507 Yohimbine HCl Atipamezole Higenamine hydrochloride Detomidine HCl Naftopidil Demethyl-Coclaurine Buflomedil HCl Fenoterol hydrobromide |
|
In vitro |
Water : 100 mg/mL
DMSO
: Insoluble
Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 548.65 | Formula | C24H38N2O6.H2SO4 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 23031-32-5 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Terbutaline hemisulfate | Smiles | CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O.CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O.OS(=O)(=O)O | ||
| Targets/IC50/Ki |
β2-adrenergic receptor
53 nM
|
|---|---|
| In vitro |
Terbutaline is a relatively selective β2-adrenergic bronchodilator that has little or no effect on alpha-adrenergic receptors. The drug has exerts a preferential effect on β2-adrenergic receptors but stimulates beta-adrenergic receptors less selectively than relatively selective beta2-agonists. Terbutaline inhibits antigen-induced histamine release from passively sensitized human lung tissue, which contributes to the clinical effectiveness of the drug during treatment of allergic asthma. Terbutaline also shows competitive reversible inhibition for all BChE variants. The dissociation constants for UU, FF and AA homozygotes are 0.18, 0.31 and 3.3 mM, respectively. |
| In vivo |
Terbutaline appears to have a greater stimulating effect on beta-receptors of the bronchial, vascular, and uterine smooth muscles (β2 receptors) than on the beta-receptors of the heart (β1 receptors). This drug relaxes smooth muscle and inhibits uterine contractions, but may also cause some cardiostimulatory effects and CNS stimulation. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06199154 | Not yet recruiting | Morbid Obesity|Pregnancy |
University of Maryland Baltimore |
May 2024 | Early Phase 1 |
| NCT05873218 | Recruiting | Labor |
Icahn School of Medicine at Mount Sinai |
June 26 2023 | Phase 4 |
| NCT03976037 | Completed | Induction of Labor |
Christiana Care Health Services |
June 4 2019 | Early Phase 1 |
| NCT03140488 | Completed | Obesity|Labor Induced|Oxytocin |
University of Arizona |
June 5 2017 | Phase 4 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.